What top creators are saying about Eli Lilly and Company(LLY)

Discussed as seeking to build a broader offering in preventive and consumer-focused medicine. The discussion was bullish on long-term potential while emphasizing clinical validation and development challenges.

Mentioned in the context of government policy and lobbying scrutiny, without a specific policy decision, company-level thesis, or recommendation.

Eli Lilly was one of the few stocks reported higher during the sell-off; the host jokingly suggested buying it but gave no investment thesis.

Described as a potential safe-haven destination for capital moving away from AI-related companies.

The guest praised monoclonal antibodies used to treat COVID-19, but the discussion focused on treatment use rather than Lilly’s overall investment prospects.

Mentioned as part of market rotation into healthcare, without detailed company-specific investment analysis.

Mentioned among reported fund holdings, without a specific investment recommendation.

Eli Lilly was mentioned in the market rundown as a price-action snapshot, without an accompanying investment thesis.

The speaker was strongly bullish, citing 39% year-over-year revenue growth, expanding GLP-1 demand, and growth across several therapeutic areas.

The guest was strongly bullish, citing strong revenue and earnings, rapid growth in Mounjaro and Zepbound, and higher 2026 revenue guidance. The thesis also includes expanding obesity-treatment demand and investment in AI, drug discovery, and acquisitions, balanced by uncertainty around future research and valuation.

The speakers were optimistic about long-term demand for weight-loss drugs and related treatments, presenting Eli Lilly as a healthcare exposure less tied to AI-investment concerns.

Strong revenue growth, an EPS beat, and a leading position in weight-loss drugs were highlighted; shares gained 7%.

The speaker was unimpressed with the quarter overall but considered margins fine and noted a significant year-over-year reduction in selling, general, and administrative expenses.

Mentioned among gainers during the session; no specific investment thesis or target was provided.

The speaker said Lilly's quarter was not that good, but provided no supporting figures or detailed criticism.

Mando viewed Lilly as relatively defensive and potentially attractive for its AI applications in pharmaceuticals, while noting broad market declines could still weigh on it.

Described as the best-looking chart.

Has the best-looking chart on the author's screen.

Lilly products, including branded tirzepatide, were mentioned in connection with Hims & Hers' platform; no standalone investment view was offered.

Cited as one of the few areas acting as a relative market refuge, but no company-specific results or outlook were discussed.

Q3 revenue was $24.4 billion, up 39% year over year, and FY26 revenue guidance was raised to $91 billion–$92 billion. The post calls the stock an obvious long-term hold and notes it has risen for 10 consecutive years.

Shares rose after results showed GLP-1-related revenue of about $10.7 billion, up 65% year over year, supporting a positive view of weight-loss drug demand.

Eli Lilly beat earnings expectations, and shares rose as much as about 9%, reaching an all-time high before easing. The discussion did not connect broader biotech advances directly to Lilly's products.

Rising sharply, according to the post.

The host was bullish on potential breakout continuation, particularly with a monthly close above $12.92, while acknowledging a possible correction.

Highlighted for its ToonLab collaborative AI initiative and described as an important AI-related company; shares reached new all-time highs during the week discussed.

Strongly bullish commentary cited ongoing healthcare demand, perceived defensiveness, AI-assisted drug discovery, and recent all-time highs.

Tulip King disclosed that Eli Lilly was his largest position by net worth and described it as exposure outside the AI-heavy equity theme, without providing a detailed thesis.

Eli Lilly was cited as an example of a stock reaching a new high, not as a specific recommendation.

Mentioned as an example of a relatively defensive stock attracting investor interest during the sell-off.

Mentioned only in the market-price rundown.

Reached an all-time high during a session when many AI-related stocks were falling.

Mentioned in a brief market update without company-specific investment analysis.

Mentioned as a possible non-AI sector area to watch, without company-specific analysis.

A bid for 1,000 shares at $800 was placed and cancellation was requested; no execution or investment thesis was confirmed.

The host reported shorting 500 shares and mentioned another short order, without explaining the rationale.

Mentioned only as Lucas's employer; the podcast provided no investment analysis, opinion, or recommendation.

The investor was long and bullish on Lilly's long-term potential, citing its pharmaceutical capabilities and direct-to-consumer efforts; clinical, regulatory, and commercial execution remain important.

The speaker said the firm was long Lilly, citing its cash resources, drug-development expertise, scale, and efforts to move closer to direct-to-consumer distribution.

The speaker says he holds Eli Lilly but provides no company-specific thesis or recommendation.

Included as a large-cap pharmaceutical name to examine and in simulated trading, without a company-specific investment thesis.

Shares rose during the session amid a broader move into healthcare.

Cited as a potential AI beneficiary in healthcare. The discussion frames AI adoption as an opportunity but does not quantify company-specific effects.

Indicated willingness to buy Oura shares in its IPO if other investors participated; no outlook or investment view on Eli Lilly stock was discussed.

The collaboration provides exposure to AI-enabled drug development, but payments depend on milestones and there is no evidence of an approved or commercially successful drug from the partnership.

Described as having been weak repeatedly, without further company-level analysis.

Eli Lilly was noted as higher during the session, without company-specific investment analysis.

The discussion mentions a claimed acquisition of a psychedelics company for about $2.8 billion, but gives no price target or investment recommendation and notes that the clinical and commercial prospects remain uncertain.

Mentioned as an example of a large pharmaceutical company in the broader drug-development landscape; no company-specific investment analysis or recommendation was provided.

Mentioned as an example of a large pharmaceutical company in the broader context of AI-assisted drug development. No Lilly-specific product, financial result, valuation, target, or recommendation was discussed.